bindarit

Bindarit is a small molecule indazolic derivative with anti-inflammatory properties. It acts primarily as a selective inhibitor of the monocyte chemotactic protein (MCP) subfamily of CC inflammatory chemokines, including MCP-1 (CCL2), MCP-3 (CCL7), and MCP-2 (CCL8), without affecting other cytokines such as IL-1, IL-6, or chemokines like IL-8 and MIP-1α[2][3][7]. Bindarit's mechanism involves downregulation of the classical NFκB pathway by reducing IκBα and p65 phosphorylation, leading to decreased nuclear translocation and DNA binding of NFκB dimers[3][4]. Additionally, it has been shown to directly interact with fatty acid binding protein 4 (FABP4), modulating p38α and AKT2 phosphorylation in a PPARγ-dependent manner[6]. Bindarit has demonstrated efficacy in experimental models for diseases such as pancreatitis, arthritis, lupus nephritis, coronary restenosis, diabetic nephropathy, and virus-induced bone loss/arthritis[1][5][8].

Other names

bindarit